Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Coates, 2015, Tailoring therapies—improving the management of early breast cancer: St Gallen International Experts Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 10.1093/annonc/mdv221
Forbes, 2008, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, Lancet Oncol, 9, 45, 10.1016/S1470-2045(07)70385-6
Becker, 2012, Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer, J Am Geriatr Soc, 60, 1761, 10.1111/j.1532-5415.2012.04107.x
Body, 2011, Increased fracture rate in women with breast cancer: a review of the hidden risk, BMC Cancer, 11, 384, 10.1186/1471-2407-11-384
Gnant, 2008, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy, Lancet Oncol, 9, 840, 10.1016/S1470-2045(08)70204-3
Gnant, 2014, Role of bisphosphonates in postmenopausal women with breast cancer, Cancer Treat Rev, 40, 476, 10.1016/j.ctrv.2013.07.003
Body, 2012, Aromatase inhibitors-induced bone loss in early breast cancer, Bonekey Rep, 1, 201, 10.1038/bonekey.2012.201
Hadji, 2011, Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment, Ann Oncol, 22, 2546, 10.1093/annonc/mdr017
Delmas, 2008, Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases, J Clin Densitom, 11, 325, 10.1016/j.jocd.2008.02.002
Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493
Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J Bone Miner Res, 8, 1137, 10.1002/jbmr.5650080915
Qi, 2014, Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials, Int J Clin Oncol, 19, 403, 10.1007/s10147-013-0561-6
Cox, 1972, Regression models and life-tables (with discussion), J R Stat Soc Series B Stat Methodol, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x
Westfall, 1999
Harbeck, 2013, St. Gallen 2013: brief preliminary summary of the consensus discussion, Breast Care, 8, 102, 10.1159/000351193
Blok, 2015, Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence, Cancer Treat Rev, 41, 271, 10.1016/j.ctrv.2015.02.004
Soiland, 2013, Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients, Acta Oncol, 52, 861, 10.3109/0284186X.2012.742963
Cheung, 2012, Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial, Lancet Oncol, 13, 275, 10.1016/S1470-2045(11)70389-8
Ito, 2012, Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer, J Clin Oncol, 30, 1468, 10.1200/JCO.2011.38.7001
Hadji, 2012, Antiresorptive treatment options and bone health in cancer patients–safety profiles and clinical considerations, Cancer Treat Rev, 38, 815, 10.1016/j.ctrv.2012.03.002
McClung, 2006, Denosumab in postmenopausal women with low bone mineral density, N Engl J Med, 354, 821, 10.1056/NEJMoa044459
Orwoll, 2012, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density, J Clin Endocrinol Metab, 97, 3161, 10.1210/jc.2012-1569
Ellis, 2008, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer, J Clin Oncol, 26, 4875, 10.1200/JCO.2008.16.3832
Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003
Bouvard, 2012, High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy, Ann Oncol, 23, 1151, 10.1093/annonc/mdr356
Irwin, 2015, Labor costs and economic impact of a primary care clinical pharmacy service on postfracture care in postmenopausal women, Pharmacotherapy, 35, 243, 10.1002/phar.1554
Shane, 2014, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res, 29, 1, 10.1002/jbmr.1998
Gnant, 2012, Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature, Cancer Treat Rev, 38, 407, 10.1016/j.ctrv.2011.09.003
Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285
Coleman, 2011, Breast-cancer adjuvant therapy with zoledronic acid, N Engl J Med, 365, 1396, 10.1056/NEJMoa1105195
Coleman, 2015, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet